Zhejiang Hisoar Pharmaceutical Co Ltd (002099) Fair Value & Analysis
Healthcare · CN · Market cap 8.5B CNY (≈ $1.3B) · ISIN CNE000001PY2
What is Zhejiang Hisoar Pharmaceutical Co Ltd really worth?
A solid business, but trading 351% above our fair value of ¥1.20.
Risks
Fair value as of: Aug 22, 2026
From 5 valuation models · updated 14 days ago
Share price −1.5% over the past month.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
What matters now
- The price sits above even our optimistic bull case (¥1.39). The favourable scenario is already priced in.
- The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
- Solid but not exceptional quality (51/100) and above fair value, neither a clear bargain nor a standout compounder.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 22, 2026.
How to read this chart
60‑month range ¥4.22 – ¥11.31 · fair‑value band ¥1.08 – ¥1.39 · the ¥5.41 price screens above the ¥1.20 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Aug 22, 2026.
Analysis
Zhejiang Hisoar Pharmaceutical Co Ltd (002099) currently trades at ¥5.41, while our model-based Fair Value estimate is ¥1.20, implying the stock looks roughly 350.9% overvalued today. The Quality Score stands at 51/100 (solid quality), in the Healthcare sector. Bull case: the Multiples group reads highest at a median of ¥3.61 per share, and 0 of the 5 models we run sit above the ¥5.41 price. Bear case: the Dividend Discount group reads lowest at ¥0.2000, and 5 of the 5 models stay below the price. Evidence for this calculation is low.
Over the trailing twelve months, Zhejiang Hisoar Pharmaceutical Co Ltd generated revenue of 1.9B CNY at a net margin of −4.0%. It earns a return on equity of −1.5%. The balance sheet holds a net cash position of 289M CNY. Fundamentals as of Aug 22, 2026
Our scenario range runs from ¥1.08 (bear case) to ¥1.39 (bull case); at ¥5.41, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 40% below its 52-week high and 6% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at −45% fair-value upside, at −78%, 002099 screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted, family-balanced blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small. Every input is real reported data, nothing guessed.
All 5 models by family
Widest divergence: Multiples (¥3.61) versus Dividend Discount (¥0.2000). Highest evidence: Owner Earnings (78).
Notify me when 002099 reaches fair value
Put 002099 on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.
Set up alert →Free, no payment details. Unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 22, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 49 · Market factors (momentum, volatility) 33
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
All values are scores from 0 to 100 (100 = best against fixed, research-based bands), not percentages. The three market factors (momentum, 52-week proximity, low volatility) are displayed but carry zero weight in the headline number: market sentiment is not a business property.
About the company
Zhejiang Hisoar Pharmaceutical Co., Ltd. engages in the manufacture of pharmaceutical products and dyes in China and internationally. The company offers antibiotics, cardiovascular, hypoglycemic, fine chemicals, formulations, intermediates, and other products.
Full company description
Zhejiang Hisoar Pharmaceutical Co., Ltd. engages in the manufacture of pharmaceutical products and dyes in China and internationally. The company offers antibiotics, cardiovascular, hypoglycemic, fine chemicals, formulations, intermediates, and other products. It also provides dyestuff, and intermediates of dyestuff and pigment; and manufactures environmental protection related equipment, medical chemical supplies and appliances, and other chemical intermediates. The company was founded in 1966 and is based in Taizhou, China.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Zhejiang Hisoar Pharmaceutical Co Ltd reported revenue of 1.9B CNY in FY2025 versus 2.5B CNY in FY2021, a compound −7.0%/yr. Reported net income was −91.1M CNY in FY2025.
002099 screens 351% overvalued. Compare with Merck KGaA →
Peer Group
Drug Manufacturers - Specialty & Generic · 608 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Drug Manufacturers - Specialty & Generic median · lower = cheaper
Strength profile in five axes (Snowflake)
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Aug 22, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Merck KGaA MRK | €140.25 | €106.48 | −24% |
| Takeda Pharmaceutical Company TAK | $18.03 | $11.11 | −38% |
| Jiangsu Hengrui Pharmaceuticals Co 600276 | ¥53.76 | ¥25.94 | −52% |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,944 | ₹989.50 | −49% |
| Galderma Group GALD | CHF 178.55 | CHF 55.07 | −69% |
| Haleon plc HLN | $10.11 | $7.64 | −24% |
| Teva Pharmaceutical Industries Limited TEVA | $36.05 | $15.33 | −57% |
| Sandoz Group SDZ | CHF 70.66 | CHF 39.21 | −45% |
| Zoetis Inc ZTS | $77.10 | $104.88 | +36% |
| Hansoh Pharmaceutical Group 3692 | HK$35.12 | HK$16.18 | −54% |
Compare Zhejiang Hisoar Pharmaceutical Co Ltd with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is Zhejiang Hisoar Pharmaceutical Co Ltd (002099) overvalued or undervalued?
What is the fair value of 002099?
What is the quality score of 002099?
What is the revenue of Zhejiang Hisoar Pharmaceutical Co Ltd (002099)?
What is the net profit margin of 002099?
Does Zhejiang Hisoar Pharmaceutical Co Ltd pay a dividend?
Watch Zhejiang Hisoar Pharmaceutical Co Ltd in the live analysis
One click puts Zhejiang Hisoar Pharmaceutical Co Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.